GNA Biosolutions Closes $6.7M Series B Financing | GenomeWeb

NEW YORK (GenomeWeb) – German molecular diagnostics firm GNA Biosolutions said today that it has closed a E6 million ($6.7 million) Series B financing round.

New investor Robert Bosch Venture Capital led the financing. Other new investors include SHS Gesellschaft für Beteiligungsmanagement GmbH, b-to-v Partners, and UnternehemerTUM-Fonds, and join existing shareholders Mey Capital Matrix, KfW, and company founders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.